-
1 week ago | 
urologytimes.com | Christian Gratzke |Benjamin P. Saylor
A recent study published in NEJM Evidence investigated the impact of conservative management, specifically an app-based therapeutic, on lower urinary tract symptoms (LUTS) in men.1 The 12-week randomized controlled trial involved over 200 men with LUTS, who were randomly assigned to an intervention group using the app in addition to their usual medication, or control group maintaining their regular medication.
-
2 weeks ago | 
urologytimes.com | Suzanne Merrill |Benjamin P. Saylor
ImmunityBio has been awarded patents for the combination of BCG plus nogapendekin alfa inbakicept (Anktiva) in bladder cancer. In a recent interview with Urology Times®, Suzanne B. Merrill, MD, FACS, was asked how she foresees the integration of this combination therapy, alongside the availability of recombinant BCG, influencing future treatment paradigms for non–muscle invasive bladder cancer.
-
2 weeks ago | 
urologytimes.com | Kate H. Kraft |Benjamin P. Saylor
In a recent interview with Urology Times®, Kate H. Kraft, MD, MHPE, FACS, FAAP, discussed a recent study regarding the use of tamsulosin (Flomax) in pediatric patients undergoing ureteroscopy.1 During the interview, she was asked about the implications of reducing repeat anesthetic exposures in children.
-
2 weeks ago | 
urologytimes.com | Landon Trost |Benjamin P. Saylor
With the FDA’s recent class-wide labeling changes for testosterone products1, urologist Landon Trost, MD, told Urology Times® it will be easier for clinicians to counsel patients regarding testosterone therapy.
-
2 weeks ago | 
urologytimes.com | Raymond Xu |Benjamin P. Saylor
Multiple reports have highlighted the utility of tools such as the Mark Cuban Cost Plus Drug Company for saving on the price of medications, including urologic medications. In a recent study published in Urogynecology, researchers sought to evaluate the Mark Cuban Cost Plus Drug Company in relation to treatments for urogynecologic conditions.1Study author Raymond Xu, MD, spoke with Urology Times® regarding the study.
-
2 weeks ago | 
urologytimes.com | Perry Xu |Benjamin P. Saylor
In the endourology space, there is a “buzz” surrounding single-use ureteroscopes, according to Perry Xu, MD. “A lot of people are using them nowadays, and part of it is because it really enhances our ability to provide guaranteed care, because we don't have to rely on the reusability of scopes. We don't have to rely on sterile processing.
-
2 weeks ago | 
urologytimes.com | Hannah Clarke |Benjamin P. Saylor
The second quarter of 2025 comes off the heels of a strong Q1, which welcomed several practice-shifting approvals in the urology space. The first of these began with an approval for gepotidacin (Blujepa) for female adults and adolescents with uncomplicated urinary tract infection (uUTI).1 Gepotidacin marks the first new oral antibiotic for uUTI in nearly 3 decades.
-
3 weeks ago | 
urologytimes.com | Kate H. Kraft |Benjamin P. Saylor
In a recent study, investigators evaluated the use of tamsulosin (Flomax) in pediatric patients undergoing ureteroscopy.1 They reported that patients who received tamsulosin had an 87% chance of having a successful URS procedure, according to senior author Kate H. Kraft, MD, MHPE, FACS, FAAP. The study findings indicate a significant age and body mass index difference between the tamsulosin and the no-tamsulosin groups.
-
3 weeks ago | 
urologytimes.com | Suzanne Merrill |Benjamin P. Saylor
For years, urologists and patients have dealt with the effects of the BCG shortage. A new expanded access program (EAP) authorized by the FDA, in which ImmunityBio is partnering with the Serum Institute of India to provide recombinant BCG (rBCG), seeks to alleviate the effects of the current shortage.1In an interview with Urology Times®, Suzanne B. Merrill, MD, FACS, discussed the impact of the BCG shortage.
-
3 weeks ago | 
urologytimes.com | Louise Kostos |Benjamin P. Saylor
In recent video interview with Urology Times®, Dr Louise Kostos was asked for take-home points regarding a recent European Urology paper in which investigators evaluated combination therapies for the treatment of locally advanced and metastatic hormone-sensitive prostate cancer.1 “I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer, and...
